Ascletis' THR- beta Agonist ASC41 Receives Approval for Clinical Trials of NASH Indication
HANGZHOU, China and SHAOXING, China, May 13, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today that it received IND approval from China's National Medical Products Administration (NMPA) for its in-house developed Category 1 Drug ASC41 to conduct clinical trials for Non-al...
Ascletis Receives IND Approval for its HIV Drug ASC09F
HANGZHOU and SHAOXING, China, April 13, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today that it received IND approval from National Medical Products Administration (NMPA) for its human immunodeficiency virus (HIV) protease inhibitor ASC09F (ASC09/Ritonavir Fixed-Dose C...
Data on NASH Candidate ASC40 to be Presented at EASL ILC 2020
HANGZHOU and SHAOXING, China, April 1, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today that its partner Sagimet Biosciences (formerly 3-V Biosciences, Inc), will present clinical and preclinical data on non-alcoholic steatohepatitis (NASH) drug candidate TVB-2640 (Ascl...
Results from First Clinical Study Using Danoprevir to Treat Naive and Experienced COVID-19 Patients
HANGZHOU and SHAOXING, China, March 25, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today the first clinical study using Ganovo®(danoprevir) to treat naive and experienced COVID-19 patients was published in medRxiv. The data from this small-sample clinical study showed ...
Progress of the Small Sample Clinical Trial of Ganovo® and Ritonavir Combination Therapy on Novel Coronavirus Pneumonia
HANGZHOU, China and SHAOXING, China, March 10, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today the progress of the small sample clinical trial of Ganovo® and Ritonavir combination therapy on Novel Coronavirus Pneumonia. One of the treatment groups in this study is the ...
Clinical Trial of Ganovo® and Ritonavir Combination Therapy on Novel Coronavirus Pneumonia
HANGZHOU and SHAOXING, China, Feb. 27, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today the advancement in Novel Coronavirus Pneumonia clinical trial of oral Ganovo® and Ritonavir combination therapy, led by Dr. Hongyi CHEN, the director of the Ninth Hospital ofNanchang...
Ascletis' IND Filing for Its Non-alcoholic Steatohepatitis (NASH) Drug Accepted by NMPA
HANGZHOU, China and SHAOXING, China, Feb. 18, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today the application for in-house developed Category 1 Drug ASC41 for clinical trials of NASH indication has been accepted byChina's National Medical Products Administration (NMPA)...
Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22, a Subcutaneously Administered PD-L1 Antibody
HANGZHOU and SHAOXING, China, Jan. 23, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (Ascletis, 1672.HK) announces today the approval for ASC22 to conduct clinical trials in chronic hepatitis B patients inChina from China's National Medical Products Administration. ASC22 is a first-in-class, subcuta...
Ascletis successfully obtained Pharmaceutical Trade License and GSP Certificate, formed a Complete Commercial Layout
HANGZHOU, China and SHAOXING, China, Nov. 29, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that Ascle...
Ascletis Appoints Former Novartis Global Head Dr. Handan He as Chief Scientific Officer
HANGZHOU, China and SHAOXING, China, Oct. 8, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that Dr.Han...
Ascletis Announces Departure of Chief Financial Officer
HANGZHOU and SHAOXING, China, Sept. 30, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces that Dr.Lindi Tan, Chi...
Ascletis Announces Departure of Chief Financial Officer
HANGZHOU and SHAOXING, China, Sept. 30, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces that Dr.Lindi Tan, Chi...
Ascletis Received IND Approval for its NASH Drug
HANGZHOU, China and SHAOXING, China, Aug. 28, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that toget...
Ascletis Opens Clinical Development Shanghai Center
HANGZHOU and SHAOXING, China, Aug. 12, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today the opening of it...
Ascletis Received IND Approval and Management Outlook of 2019 and Beyond
HANGZHOU and SHAOXING, China, Aug. 5, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that it received I...
3-V Biosciences Commences Dosing in Phase 2 Clinical Study of the FASN Inhibitor TVB-2640 in Patients with NASH
SAN MATEO, Calif. and HANGZHOU and SHAOXING, China, May 1, 2019 /PRNewswire/ -- 3-V Biosciences, Inc. (3-V Biosciences) and Ascletis Pharma Inc. (Ascletis, 1672.HK)announced that 3-V Biosciences has recently dosed its first patient in a Phase 2 clinical trial of the FASN (fatty acid synthase) inh...
Ganovo is Eligible for the Basic Medical Insurance of Zhejiang Province - Reimbursement-by-disease
HANGZHOU and SHAOXING, China, April 15, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (Ascletis, 1672.HK), a commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that according to the official...
Ascletis Appoints Former MSD Global Vice President Dr. Zhengqing Li as Chief Medical Officer and President of R&D Greater China
HANGZHOU, China and SHAOXING, China, March 1, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that Dr. Z...
Ascletis and 3-V Biosciences Announce NASH Strategic License and Series E Financing
HANGZHOU and SHAOXING, China and SAN FRANCISCO, Feb. 13, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (Ascletis, 1672.HK) and 3-V Biosciences, Inc. (3-V Biosciences) jointly announce today that Ascletis, through its subsidiary, and 3-V Biosciences have entered into an exclusive license agreement for...
Ascletis and Alphamab Announce Strategic Collaboration and Licensing Agreement for Anti-PD-L1 to Treat Hepatitis B and Other Viral Diseases
HANGZHOU, China and SHAOXING, China and SUZHOU, China, Jan. 14, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (Ascletis, 1672.HK) and Suzhou Alphamab Co., Ltd. (Alphamab) jointly announce today that Ascletis' subsidiary and Alphamab have entered into a strategic collaboration and exclusive licensing ...
